SP1 and breast cancer: MIT was reported to sensitize breast cancer stem cells to doxorubicin by transcriptional suppression of chemoresistant and self-renewal genes, including ABCG2, ABCC1, Bcl-2, XIAP, Oct4 and Nanog, through inhibiting Sp1 recruitment to their promoters48.